ARTICLE | Clinical News
Vidaza azacitidine regulatory update
September 27, 2004 7:00 AM UTC
The EMEA accepted for review an MAA for Vidaza azacitidine to treat myelodysplastic syndromes (MDS). The nucleoside analog that causes DNA hypomethylation has Orphan Product designation from the EMEA....